TITLE

New and Emerging Drugs and Targets for Type 2 Diabetes: Reviewing the Evidence

AUTHOR(S)
Miller, Brien Rex; Hanh Nguyen; Jia-Haur Hu, Charles; Chihyi Lin; Quang T. Nguyen
PUB. DATE
November 2014
SOURCE
American Health & Drug Benefits;Nov2014, Vol. 7 Issue 8, p452
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
BACKGROUND: Diabetes is a deadly and costly disease. The number of adults in the United States with newly diagnosed diabetes has nearly tripled from 1980 to 2011. At the current pace, 1 in 3 US adults will have diabetes in their lifetime. Currently, 14 classes of drugs are available to treat type 2 diabetes mellitus, but only 36% of patients with type 2 diabetes achieve glycemic control with the currently available therapies. Therefore, new treatment options are desperately needed. DISCUSSION: Despite the availability of many pharmacotherapies, in 2011 an estimated 3.1 million (14.9%) patients with type 2 diabetes still reported not taking medications to treat their diabetes. Patient compliance is a major obstacle facing practicing clinicians on a daily basis. New treatment options are desperately needed, but efficacy and tolerability are no longer the only criteria contributing to the success of a drug. Ease of administration, convenient dosing frequency, being weight control friendly, and having a low risk for hypoglycemia are important factors for the survival of a new drug in the US healthcare system. The present review is focused on important new drugs and drug classes in the pipeline, as well as on recently approved drugs, including sodium glucose cotransporter-2 inhibitors, glucagon-like peptide-1 agents, and new insulin therapies, as well as on the technologic improvements in the delivery and dosing frequency of some of the currently available drugs. CONCLUSIONS: In the United States, diabetes can be expected to continue to wreak significant human and financial tolls. The associated complications will continue to climb if they are not controlled and stopped. New therapies for diabetes are clearly needed that will better address these unmet needs. The common threads among the emerging therapies are their convenience of administration and dosing frequency, which are important to the improvement of patient adherence.
ACCESSION #
100237379

 

Related Articles

  • Exenatide Injection.  // AHFS Consumer Medication Information;Aug2020, p1 

    Exenatide is used along with diet and exercise to treat type 2 diabetes (condition in which the body does not use insulin normally and therefore cannot control the amount of sugar in the blood). Exenatide is in a class of medications called incretin mimetics. It works by stimulating the pancreas...

  • Regulatory Roundup.  // BioWorld Today;3/17/2009, Vol. 20 Issue 50, p3 

    The article announces investigational new drug approval for Melior Discovery Incorporated's novel diabetes drug MLR-1023. The Exton, Pennsylvania-based company announced that the U.S. Food & Drug Administration approved its application for clinical studies of MLR-1023, a first-in-class kinase...

  • Extended-Release Glycemic Control OK'd.  // Journal of Gerontological Nursing;Jul2009, Vol. 35 Issue 7, p8 

    The article reports that ACTOplus met® XR has been approved by the U.S. Food and Drug Administration (FDA) as an adjunct to diet and exercise in treating type 2 diabetes. The ACTOplus, which is considered as the first prescription oral antidiabetic with the extended-release form of metformin,...

  • A new drug belonging to a novel class of drugs for type 2 diabetes. Sivagnanam, G. // Journal of Pharmacology & Pharmacotherapeutics;Jul-Sep2013, Vol. 4 Issue 3, p224 

    The article offers information on the Sodium-glucose contransporter 2(SGLT 2) inhibitor, Invokana treatment for type 2 diabetes which have been approved by the Food and Drug Administration (FDA) in the U.S. It states that the SGLT 2 do not simulate insulin secretion and are expected to be...

  • Selling Safety—Lessons From Muraglitazar. Brophy, James M. // JAMA: Journal of the American Medical Association;11/23/2005, Vol. 294 Issue 20, p2633 

    The article presents an editorial regarding the U.S. Food and Drug Administration's (FDA) approval of the drug muraglitazar, a dual-peroxisome proliferator-activated receptor for the treatment of type 2 diabetes. The FDA reviewed muraglitazar's efficacy and safety and recommended drug approval....

  • Adding Once-Daily Lixisenatide for Type 2 Diabetes Inadequately Controlled With Newly Initiated and Continuously Titrated Basal Insulin Glargine. RIDDLE, MATTHEW C.; FORST, THOMAS; ARONSON, RONNIE; SAUQUE-REYNA, LEOBARDO; SOUHAMI, ELISABETH; SILVESTRE, LOUISE; LIN PING; ROSENSTOCK, JULIO // Diabetes Care;Sep2013, Vol. 36 Issue 9, p2497 

    OBJECTIVE--When oral therapy for type 2 diabetes is ineffective, adding basal insulin improves glycemic control. However, when glycated hemoglobin (HbA1c) remains elevated because of postprandial hyperglycemia, the next therapeutic step is controversial. We examined the efficacy and safety of...

  • Initiation and Gradual Intensification of Premixed Insulin Lispro Therapy Versus Basal ± Mealtime Insulin in Patients With Type 2 Diabetes Eating Light Breakfasts. Giugliano, Dario; Tracz, Mariusz; Shah, Sanjiv; Calle-Pascual, Alfonso; Mistodie, Cristina; Duarte, Rui; Sari, Ramazan; Woo, Vincent; Jiletcovici, Alina O.; Deinhard, Jürgen; Wille, Simone A.; Kiljański, Jacek // Diabetes Care;Feb2014, Vol. 37 Issue 2, p372 

    OBJECTIVE We compared two strategies initiating and intensifying insulin treatment and tested for noninferiority of premixed insulin to basal ± mealtime insulin analog in patients eating light breakfasts. RESEARCH DESIGN AND METHODS This randomized, open-label, 48-week study compared two...

  • Insulin glulisine provides improved glycemic control in patients with type 2 diabetes. Dailey, George; Rosenstock, Julio; Moses, Robert G.; Ways, Kirk // Diabetes Care;Oct2004, Vol. 27 Issue 10, p2363 

    Objective: Insulin glulisine is a novel analog of human insulin designed for use as a rapid-acting insulin. This study compared the safety and efficacy of glulisine with regular human insulin (RHI) in combination with NPH insulin.Research Design and Methods: In total,...

  • New Options in Insulin Therapy. SARAIYA, NIDHI; MARTIN, SPENCER T. // Connecticut Medicine;Oct2015, Vol. 79 Issue 9, p553 

    The article presents a study on the options of using insulin therapy for the treatment of type 1 diabetes mellitus (TlDM) and type 2 diabetes mellitus (T2DM). Topics discussed include the approval of the insulin glargine 300 units/mL formulation by the U.S. Food and Drug Administration (FDA),...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics